Skip to content Skip to footer
Caliway Biopharmaceuticals Co., Ltd
Order
Caliway Biopharmaceuticals Co., Ltd
Order
Caliway Biopharmaceuticals Co., Ltd
Order
Close

A TREATMENT THAT CAN REVERSE ARTHRITIS New Promising Treatment to Slow and Halt the Progress of Osteoarthritis CALIWAY – CATCH YOUR AMAZING WAY We Are Dedicated to Breakthrough Drug Discovery in Aesthetics and Chronic Inflammatory Diseases SELF-CONFIDENCE BOOSTING AND GENERAL HEALTH IMPROVING We Develop Innovative Treatments to Meet the Diverse Clinical Needs of Central Obesity and Fatty Liver CALIWAY – CATCH YOUR AMAZING WAY We Are Dedicated to Breakthrough with First-in-class Lipolysis Injection Biomedical Researchers and Laboratory Experts at Caliway

RESEARCH
AND
DEVELOPMENT

  • Aesthetics
    Localized Fat Reduction, Cellulite,
    Hyperpigmentation, Skin Aging
  • Therapeutics
    Dercum’s Disease, Osteoarthritis, Central Obesity

CBL-514 injecion

CBL-514, Caliway's leading product, is expected to effectively reduce subcutaneous fat precisely at the injection site by causing targeted adipocyte apoptosis without damaging other tissues and cells.
Read more

CBL-520 injection

CBL-520, Caliway's leading product, is expected to effectively reduce subcutaneous fat precisely at the injection site by causing targeted adipocyte apoptosis without damaging other tissues and cells.
Read more

CBL-521 injecion

CBL-521, Caliway's leading product, is expected to effectively reduce subcutaneous fat precisely at the injection site by causing targeted adipocyte apoptosis without damaging other tissues and cells.
Read more

ABOUT

In Caliway, we are driven to breakthrough drug discovery of novel small-molecule therapeutics for medical aesthetics and inflammatory disease. By developing innovative drugs, we aim to provide new treatment options for the indications in which clinical needs remain unmet.

Learn More

NEWS

In Caliway, we are driven to breakthrough drug discovery of novel small-molecule therapeutics for medical aesthetics and inflammatory disease. By developing innovative drugs, we aim to provide new treatment options for the indications in which clinical needs remain unmet.

Learn More

FDA IND Clearance for CBL-0201WR—Caliway has cleared its Investigational New Drug application for CBL-0201WR, a Phase 2 trial evaluating CBL-514 in combination with tirzepatide.

Caliway’s CBL-514 Combination

Asia-Pacific Strategic Milestone—Caliway has submitted an Investigational New Drug application for its Phase 1 clinical study (CBL-0102) of CBL-514 to China’s NMPA CDE, launching localized fat reduction drug development in the Chinese market.

Caliway Initiates CBL-514

Phase 2 IND Submitted to FDA—Caliway has submitted an Investigational New Drug (IND) application to the U.S. FDA for CBL-0201WR, a multicenter Phase 2 clinical study to evaluate CBL-514 in combination with Zepbound® (tirzepatide, Eli Lilly).

Targeting the Pain Point of Weight Regain in GLP